Fused pentacyclic imidazole derivatives

US10906919B2 · kind B2 · utility

Assignees

• UCB BIOPHARMA SRL · BE
• Sanofi · FR

Inventors

• Teresa De Haro Garcia · Slough, GB
• Michael Deligny · Brussels, BE
• Jag Paul Heer · Brussels, BE
• Joanna Rachel Quincey · Slough, GB
• Mengyang Xuan · Slough, GB
• Zhaoning Zhu · Plainsboro, US
• Daniel Christopher Brookings · Slough, GB
• Mark Daniel Calmiano · Slough, GB
• Yves Evrard · Brussels, BE
• Martin Clive Hutchings · Slough, GB
• James A. Johnson · Lawrenceville, US
• Sophie Jadot · Brussels, BE
• Jean Keyaerts · Brussels, BE
• Malcolm Mac Coss · Seabrook Island, US
• Matthew Duncan Selby · Sandwich, GB
• Michael Alan Shaw · Slough, GB
• Dominique Swinnen · Braine-l'Alleud, BE
• Laurent Schio · Paris, FR
• Yann Foricher · Riedisheim, FR
• Bruno Filoche-Romme · Paris, FR

Key dates

• Filing date: Dec 14, 2018
• Grant date: Feb 2, 2021
• Expiry date: Dec 14, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/1804
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.